- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT04919512
방광의 근육 침습성 요로상피암 참가자를 대상으로 한 TAR-200과 세트렐리맙 및 세트렐리맙 단독 요법에 대한 연구 (SunRISe-4)
근치적 방광절제술이 예정되어 있고 백금- 기반 신 보조 화학 요법
The purpose of this study is to evaluate the anti-tumor effects of TAR-200 in combination with intravenous (IV) cetrelimab and IV cetrelimab alone.
연구 개요
상세 설명
Bladder cancer is the tenth most common malignancy worldwide. Approximately 25 percent (%) of all new bladder cancer participants present with muscle invasive bladder cancer (MIBC) at the time of diagnosis, and roughly 50% will ultimately develop distant metastases. The TAR-200/ gemcitabine (JNJ-17000139) product is an intravesical drug delivery system regulated as an investigational drug. The drug constituent consists of gemcitabine minitablets and osmotic minitablets. Cetrelimab (JNJ-63723283) is a fully human immunoglobulin G4 (IgG4) kappa monoclonal antibody (mAb) that binds programmed-cell death protein (PD)-1. The standard of care in MIBC includes radical cystectomy (RC) with urinary diversion and is considered the preferred treatment option for participants who are considered surgical candidates. Study consists of a Screening phase, Treatment phase and follow-up phase. The total duration of study will be up to 2 years and 6 months. Efficacy, safety, pharmacokinetics (PK), and biomarkers will be assessed at specific time points during this study.
연구 유형
등록 (실제)
단계
- 2 단계
확장된 액세스
연락처 및 위치
연구 장소
-
-
-
Almelo, 네덜란드, 7600
- Ziekenhuisgroep Twente
-
Den Ham, 네덜란드, 2545 AA
- Haga ziekenhuis
-
Nijmegen, 네덜란드, 6532SZ
- Canisius-Wilhelmina Ziekenhuis
-
Nijmegen, 네덜란드, 6525 GA
- Radboud Umcn
-
-
-
-
-
Busan, 대한민국, 612-030
- Inje University Haeundae Paik Hospital
-
Daegu, 대한민국, 41404
- Kyungpook National University Chilgok Hospital
-
Daegu, 대한민국, 42601
- Keimyung University Dongsan Hospital
-
Ganggu, 대한민국, 06351
- Samsung Medical Center
-
Goyang, 대한민국, 10408
- National Cancer Center
-
Seoul, 대한민국, 03080
- Seoul National University Hospital
-
Seoul, 대한민국, 03722
- Severance Hospital
-
Seoul, 대한민국, 02841
- Korea University Anam Hospital
-
Seoul, 대한민국, 06273
- Gangnam Severance Hospital
-
Seoul, 대한민국, 06591
- The Catholic University of Korea Seoul St Mary s Hospital
-
Yangsan, 대한민국, 50612
- Pusan National University Yangsan Hospital
-
-
-
-
-
Berlin, 독일, 10967
- Vivantes Klinikum Am Urban
-
Braunschweig, 독일, 38118
- Staedtisches Klinikum Braunschweig
-
Frankfurt am Main, 독일, 60431
- Agaplesion Frankfurter Diakonie Kliniken GmbH, Markus Krankenhaus
-
Halle, 독일, 06120
- Universitaetsklinikum Halle Saale
-
Herne, 독일, 44625
- Marien hospital Herne
-
Münsterhausen, 독일, 48149
- Universitatsklinikum Munster
-
-
-
-
Alabama
-
Birmingham, Alabama, 미국, 35294
- University of Alabama at Birmingham
-
-
Arizona
-
Tucson, Arizona, 미국, 85741
- Urological Associates of Southern Arizona, P.C.
-
-
Arkansas
-
Little Rock, Arkansas, 미국, 72211
- Arkansas Urology
-
Little Rock, Arkansas, 미국, 72205
- UAMS Winthrop P. Rockefeller Cancer Institute
-
-
California
-
Duarte, California, 미국, 91010
- City of Hope
-
San Diego, California, 미국, 92123
- Genesis Research
-
-
Colorado
-
Golden, Colorado, 미국, 80401
- Colorodo Urology- St. Anthony Hospital
-
-
Florida
-
Jacksonville, Florida, 미국, 32224
- Mayo Clinic
-
Jacksonville, Florida, 미국, 32209
- University of Florida Health Jacksonville
-
Miami, Florida, 미국, 33176
- Baptist Hospital of Miami
-
-
Georgia
-
Atlanta, Georgia, 미국, 30322
- Winship Cancer Institute Emory University
-
-
Illinois
-
Astoria, Illinois, 미국, 11102
- Mount Sinai Queens Infusion Center
-
Lisle, Illinois, 미국, 60532
- DuPage Medical Group
-
-
Indiana
-
Indianapolis, Indiana, 미국, 46260
- Urology of Indiana
-
Jeffersonville, Indiana, 미국, 47130
- First Urology
-
-
Kentucky
-
Louisville, Kentucky, 미국, 40202
- University of Louisville - James Graham Brown Cancer Center
-
-
Maryland
-
Baltimore, Maryland, 미국, 21218
- Penn Medicine - PerelmanCenter for Advanced Medicine
-
Baltimore, Maryland, 미국, 21201
- University Of Maryland Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02115
- Brigham and Women's Hospital
-
-
Michigan
-
Troy, Michigan, 미국, 48084
- Michigan Institute of Urology, PC
-
-
Minnesota
-
Minneapolis, Minnesota, 미국, 55455
- University Of Minnesota
-
Rochester, Minnesota, 미국, 55905
- Mayo Clinic 1
-
-
Missouri
-
Columbia, Missouri, 미국, 65201
- Ellis Fischel Cancer Center
-
St Louis, Missouri, 미국, 63141
- David C. Pratt Cancer Center
-
St Louis, Missouri, 미국, 63110-1010
- Washington University School Of Medicine - Center For Advanced Medicine (CAM)
-
-
New Jersey
-
New Brunswick, New Jersey, 미국, 08901
- Robert Wood Johnson University Hospital
-
-
New York
-
New York, New York, 미국, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, 미국, 10017
- New York University Langone Medical Center
-
Syracuse, New York, 미국, 13202
- SUNY Upstate Medical University
-
Syracuse, New York, 미국, 13210
- Associated Medical Professionals
-
The Bronx, New York, 미국, 10467
- Montefiore Medical Center
-
-
North Carolina
-
Winston-Salem, North Carolina, 미국, 27103
- Wake Forest University Baptist Medical Center (WFUBMC) - Comprehensive Cancer Center
-
-
Ohio
-
Columbus, Ohio, 미국, 43210
- The Ohio State University
-
-
Pennsylvania
-
Bala-Cynwyd, Pennsylvania, 미국, 19004
- MidLantic Urology
-
Pittsburgh, Pennsylvania, 미국, 15232
- University Of Pittsburgh Medical Center UPMC Hillman Cancer Center
-
-
South Carolina
-
Myrtle Beach, South Carolina, 미국, 29572
- Carolina Urologic Research Center
-
-
Tennessee
-
Nashville, Tennessee, 미국, 37209
- Urology Associates
-
-
Texas
-
Houston, Texas, 미국, 77027
- Houston Metro Urology
-
San Antonio, Texas, 미국, 78229
- Urology San Antonio Research
-
-
Utah
-
Salt Lake City, Utah, 미국, 84112
- Huntsman Cancer Institute
-
-
Washington
-
Seattle, Washington, 미국, 98195
- University of Washington School of Medicine
-
-
-
-
-
Brugge (Bruges), 벨기에, 8000
- AZ Sint Jan Brugge Oostende AV
-
Brugge (Bruges), 벨기에, 8310
- Algemeen Ziekenhuis Sint-Jan
-
Genk, 벨기에, 3600
- Ziekenhuis Oost-Limburg
-
Haine-Saint-Pierre, 벨기에, 7100
- Hopital de Jolimont
-
Merksem, 벨기에, 2170
- ZNA Jan Palfijn
-
Mons, 벨기에, 7000
- Centre Interuniversitaire Ambroise Pare - Ambroise Paré
-
-
-
-
-
Barcelona, 스페인, 08041
- Fund. Puigvert
-
Granada, 스페인, 18016
- Hosp. Univ. San Cecilio
-
La Coruña (A Coruña), 스페인, 15006
- Hosp Univ A Coruna
-
Madrid, 스페인, 28041
- Hospital Universitario 12 de Octubre
-
Madrid, 스페인, 28027
- Clinica Univ. de Navarra
-
Málaga, 스페인, 29010
- Hosp Virgen de La Victoria
-
Santander, 스페인, 39002
- Hosp. Univ. Marques de Valdecilla
-
-
-
-
-
London, 영국, EC1A 7BE
- Barts Health NHS Trust
-
Preston, 영국, PR2 9HT
- Lancashire Teaching Hospitals NHS Foundation Trust Royal Preston Hospital
-
-
-
-
-
Haifa, 이스라엘, 3109601
- Rambam Health Care Campus
-
Haifa, 이스라엘, 3436212
- Carmel Medical Center
-
Petah Tikva, 이스라엘, 49372
- Rabin Medical Center - Hasharon Hospital
-
Ramat Gan, 이스라엘, 52621
- The Chaim Sheba Medical Center
-
Tel Aviv, 이스라엘, 6423906
- Tel Aviv Sourasky Medical Center
-
Yeruham, 이스라엘, 91120
- Hadassah Medical Center
-
-
-
-
-
Avellino, 이탈리아, 83100
- Ospedale San Giuseppe Moscati di Avellino
-
Carpi, 이탈리아, 41012
- Ospedale Civile Ramazzini
-
Genova, 이탈리아, 16100
- SPDC Villa Scassi
-
Milan, 이탈리아, 20141
- Istituto Europeo di Oncologia
-
Milan, 이탈리아, 20132
- IRCCS Ospedale San Raffaele
-
Milan, 이탈리아, 20133
- Istituto Dei Tumori Di Milano
-
Naples, 이탈리아, 80131
- Istituto Nazionale Tumori Fondazione G. Pascale
-
Pisa, 이탈리아, 56126
- Azienda Ospedaliero Universitaria Pisana
-
Pozzuoli, 이탈리아, 80078
- ASL Napoli 2 Nord-SM delle Grazie Hospital
-
Romagnano, 이탈리아, 00144
- Istituto Nazionale Tumori Regina Elena
-
Rozzano, 이탈리아, 20089
- IRCCS Istituto Clinico Humanitas
-
Torino, 이탈리아, 10126
- Azienda Ospedaliera Universitaria Citta della Salute e della Scienza di Torino
-
-
-
-
-
Bordeaux, 프랑스, 33000
- Clinique Tivoli Ducos
-
Brest, 프랑스, 29200
- ICH Hopital A. Morvan
-
Créteil, 프랑스, 94000
- Hopital Henri Mondor
-
Lille, 프랑스, 59000
- Hôpital Privé Le Bois
-
Limoges, 프랑스, 87000
- Polyclinique de Limoges - Francois Chenieux
-
Marseille, 프랑스, 13005
- Hopital de la Timone
-
Montpellier, 프랑스, 34295
- CHU Montpellier
-
Nîmes, 프랑스, 30029
- CHU Nimes
-
Paris, 프랑스, 75877
- Hopital Bichat Claude Bernard
-
Paris, 프랑스, 75015
- Hopital Europeen Georges-Pompidou
-
Pierre-Bénite, 프랑스, 69495
- Hospices Civils de Lyon HCL
-
Quint-Fonsegrives, 프랑스, 31130
- Clinical La Croix Du Sud - Ramsay Santé
-
Toulon, 프랑스, 83041
- HIA se Sainte-Anne - Toulon
-
Toulouse, 프랑스, 31076
- Clinique Pasteur
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Histologically proven, cT2-T4a N0, M0 infiltrating urothelial carcinoma of the bladder. Initial diagnosis must have been within 120 days of randomization date. Participants with variant histologic subtypes are allowed if tumor(s) demonstrate urothelial predominance. However, the presence of small cell or neuroendocrine variants will make a participant ineligible
- Participants with no residual tumor, or intravesical tumor size of less than or equal to (<=)3 centimeter (cm) following transurethral resection of bladder tumor (TURBT) are eligible; debulking TURBT for any residual disease is encouraged but not mandated. Participants with persistent tumors greater than (>)3 cm at screening must undergo a second debulking, re-staging TURBT. Participants will be ineligible if any individual tumor is >3 cm after debulking TURBT
- Deemed eligible for and willing to undergo RC by the operating urologist
- Eastern Cooperative Oncology Group (ECOG) performance status Grade 0 or 1
- Thyroid function tests within normal range or stable on hormone supplementation per investigator assessment. Investigators may consult an endocrinologist for participant eligibility assessment in the case of equivocal or marginal tests results
- All adverse events associated with any prior surgery must have resolved to common terminology criteria for adverse events (CTCAE) version 5.0 Grade less than (<) 2 prior to randomization
Exclusion Criteria:
- Must not have received prior systemic chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to starting study treatment
- Participants must not have evidence of cT4b, or N1-3, or M1 disease based on central radiology staging (chest, abdomen, and pelvis must be performed using computed tomography [CT] or magnetic resonance imaging [MRI]) within 42 days prior to randomization
- Presence of any bladder or urethral anatomic feature that, in the opinion of the Investigator, may prevent the safe placement, indwelling use, or removal of TAR-200
- Prior systemic chemotherapy for urothelial cell carcinoma of the bladder at any time
- Currently participating or has participated in a study of an investigational agent and received study therapy or investigational device within 4 weeks prior to enrollment
- Participants with evidence of bladder perforation during diagnostic cystoscopy. Participant is eligible if perforation has resolved prior to dosing
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Cohort 1: TAR-200 + Cetrelimab
Participants will receive TAR-200 in combination with cetrelimab. |
Cetrelimab will be administered.
다른 이름들:
TAR-200 will be administered.
다른 이름들:
|
|
실험적: Cohort 2: Cetrelimab
Participants will receive cetrelimab. |
Cetrelimab will be administered.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Pathologic Complete Response (pCR) Rate
기간: At Week 12
|
pCR was defined as percentage of participants who achieved complete pathologic response. Complete pathologic response is defined as ypT0N0 (no evidence of disease) as assessed by pathologic evaluation on radical cystectomy (RC) specimen. pCR was determined by central pathologic review. |
At Week 12
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
Common Terminology Criteria for Adverse Event(CTCAE) 버전 5 등급에 따른 치료 중 발생한 이상반응을 경험한 참가자 수
기간: 주기 1일차부터 124주까지
|
주기 1일차부터 124주까지
|
|
공통 유해사건 평가 기준(CTCAE)에 따른 기준선 후 최악의 검사실 수치를 보인 참가자 수
기간: 사이클 1일차부터 124주차까지
|
사이클 1일차부터 124주차까지
|
|
재발없는 생존 (RFS)
기간: 사이클 1일차부터 124주차까지
|
사이클 1일차부터 124주차까지
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
간행물 및 유용한 링크
일반 간행물
- Necchi A, Guerrero-Ramos F, Crispen PL, Herrera-Imbroda B, Garje R, Powles T, Peyton CC, Pradere B, Ku JH, Shore N, Bogemann M, Preston MA, Xylinas E, Sanchez de Llano C, Hasan M, Stitou H, Bhanvadia S, Sweiti H, Psutka SP. TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open-label phase 2 trial. Lancet Oncol. 2025 Oct;26(10):1312-1322. doi: 10.1016/S1470-2045(25)00358-4. Epub 2025 Aug 27.
- Necchi A, Guerrero-Ramos F, Crispen PL, Herrera-Imbroda B, Garje R, Szabados B, Peyton CC, Pradere B, Ku JH, Shore N, Bogemann M, Preston MA, Xylinas E, Sanchez de Llano C, Gong C, Hasan M, Urtishak K, Battaglia S, Stitou H, Bhanvadia S, Sweiti H, Psutka SP. Gemcitabine Intravesical System Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer: SunRISe-4 Primary Analysis and Biomarker Results. J Clin Oncol. 2026 Mar;44(7):586-597. doi: 10.1200/JCO-25-02382. Epub 2025 Dec 3.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- CR109044
- 2020-005565-13 (EudraCT 번호)
- 17000139BLC2002 (기타 식별자: Janssen Research & Development, LLC)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .